104 related articles for article (PubMed ID: 26058984)
41. [Fabry disease and cystinosis, two lysosomal diseases: similarities and differences].
Grünfeld JP; Servais A
Rev Med Interne; 2010 Dec; 31 Suppl 2():S226-8. PubMed ID: 21211669
[TBL] [Abstract][Full Text] [Related]
42. A Phase 2 study of migalastat hydrochloride in females with Fabry disease: selection of population, safety and pharmacodynamic effects.
Giugliani R; Waldek S; Germain DP; Nicholls K; Bichet DG; Simosky JK; Bragat AC; Castelli JP; Benjamin ER; Boudes PF
Mol Genet Metab; 2013 May; 109(1):86-92. PubMed ID: 23474038
[TBL] [Abstract][Full Text] [Related]
43. Cellular and tissue localization of globotriaosylceramide in Fabry disease.
Askari H; Kaneski CR; Semino-Mora C; Desai P; Ang A; Kleiner DE; Perlee LT; Quezado M; Spollen LE; Wustman BA; Schiffmann R
Virchows Arch; 2007 Oct; 451(4):823-34. PubMed ID: 17674039
[TBL] [Abstract][Full Text] [Related]
44. Enzymatic corrections for cells derived from Fabry disease patients by a recombinant adenovirus vector.
Ohsugi K; Kobayashi K; Itoh K; Sakuraba H; Sakuragawa N
J Hum Genet; 2000; 45(1):1-5. PubMed ID: 10697955
[TBL] [Abstract][Full Text] [Related]
45. Interdisciplinary approach towards female patients with Fabry disease.
Weidemann F; Niemann M; Sommer C; Beer M; Breunig F; Wanner C
Eur J Clin Invest; 2012 Apr; 42(4):455-62. PubMed ID: 22049975
[TBL] [Abstract][Full Text] [Related]
46. Fabry disease: reduced activities of respiratory chain enzymes with decreased levels of energy-rich phosphates in fibroblasts.
Lücke T; Höppner W; Schmidt E; Illsinger S; Das AM
Mol Genet Metab; 2004 May; 82(1):93-7. PubMed ID: 15110329
[TBL] [Abstract][Full Text] [Related]
47. Purification and characterization of human alpha-galactosidase A expressed in insect cells using a baculovirus vector.
Chen Y; Jin M; Goodrich L; Smith G; Coppola G; Calhoun DH
Protein Expr Purif; 2000 Nov; 20(2):228-36. PubMed ID: 11049747
[TBL] [Abstract][Full Text] [Related]
48. ConA-mediated binding and uptake of purified alpha-galactosidase A in Fabry fibroblasts.
Hasholt L; Sørensen SA
Exp Cell Res; 1983 Oct; 148(2):405-11. PubMed ID: 6313412
[TBL] [Abstract][Full Text] [Related]
49. A modified lipid composition in Fabry disease leads to an intracellular block of the detergent-resistant membrane-associated dipeptidyl peptidase IV.
Maalouf K; Jia J; Rizk S; Brogden G; Keiser M; Das A; Naim HY
J Inherit Metab Dis; 2010 Aug; 33(4):445-9. PubMed ID: 20495958
[TBL] [Abstract][Full Text] [Related]
50. Angiokeratoma corporis diffusum (Fabry disease). A lysosomal disease.
Hashimoto K; Lieberman P; Lamkin N
Arch Dermatol; 1976 Oct; 112(10):1416-23. PubMed ID: 183606
[TBL] [Abstract][Full Text] [Related]
51. Angiokeratoma corporis diffusum (Fabry disease).
Karen JK; Hale EK; Ma L
Dermatol Online J; 2005 Dec; 11(4):8. PubMed ID: 16403380
[TBL] [Abstract][Full Text] [Related]
52. Later-onset Fabry disease: an adult variant presenting with the cramp-fasciculation syndrome.
Nance CS; Klein CJ; Banikazemi M; Dikman SH; Phelps RG; McArthur JC; Rodriguez M; Desnick RJ
Arch Neurol; 2006 Mar; 63(3):453-7. PubMed ID: 16533976
[TBL] [Abstract][Full Text] [Related]
53. Non-viral, integrin-mediated gene transfer into fibroblasts from patients with lysosomal storage diseases.
Estruch EJ; Hart SL; Kinnon C; Winchester BG
J Gene Med; 2001; 3(5):488-97. PubMed ID: 11601762
[TBL] [Abstract][Full Text] [Related]
54. Chronic kidney disease and an uncertain diagnosis of Fabry disease: approach to a correct diagnosis.
van der Tol L; Svarstad E; Ortiz A; Tøndel C; Oliveira JP; Vogt L; Waldek S; Hughes DA; Lachmann RH; Terryn W; Hollak CE; Florquin S; van den Bergh Weerman MA; Wanner C; West ML; Biegstraaten M; Linthorst GE
Mol Genet Metab; 2015 Feb; 114(2):242-7. PubMed ID: 25187469
[TBL] [Abstract][Full Text] [Related]
55. Distribution of alpha-galactosidase A in normal human kidney and renal accumulation and distribution of recombinant alpha-galactosidase A in Fabry mice.
Christensen EI; Zhou Q; Sørensen SS; Rasmussen AK; Jacobsen C; Feldt-Rasmussen U; Nielsen R
J Am Soc Nephrol; 2007 Mar; 18(3):698-706. PubMed ID: 17287429
[TBL] [Abstract][Full Text] [Related]
56. Synergy between the pharmacological chaperone 1-deoxygalactonojirimycin and agalsidase alpha in cultured fibroblasts from patients with Fabry disease.
Pisani A; Porto C; Andria G; Parenti G
J Inherit Metab Dis; 2014 Jan; 37(1):145-6. PubMed ID: 23974650
[No Abstract] [Full Text] [Related]
57. Generation of the human induced pluripotent stem cell line (UKWNLi001-A) from skin fibroblasts of a woman with Fabry disease carrying the X-chromosomal heterozygous c.708 G > C (W236C) missense mutation in exon 5 of the alpha-galactosidase-A gene.
Klein T; Günther K; Kwok CK; Edenhofer F; Üçeyler N
Stem Cell Res; 2018 Aug; 31():222-226. PubMed ID: 30130681
[TBL] [Abstract][Full Text] [Related]
58. Cardiac valvular anomalies in Fabry disease. Clinical, morphologic, and biochemical studies.
Desnick RJ; Blieden LC; Sharp HL; Hofschire PJ; Moller JH
Circulation; 1976 Nov; 54(5):818-25. PubMed ID: 824066
[TBL] [Abstract][Full Text] [Related]
59. Fluorescent probes for selective protein labeling in lysosomes: a case of α-galactosidase A.
Bohl C; Pomorski A; Seemann S; Knospe AM; Zheng C; Krężel A; Rolfs A; Lukas J
FASEB J; 2017 Dec; 31(12):5258-5267. PubMed ID: 28821638
[TBL] [Abstract][Full Text] [Related]
60. Development of Organelle Replacement Therapy Using a Stearyl-Polyhistidine Peptide against Lysosomal Storage Disease Cells.
Hayashi T; Okamoto R; Kawano T; Iwasaki T
Molecules; 2019 Aug; 24(16):. PubMed ID: 31426598
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
